RESEARCH AND DEVELOPMENT COSTS. U.S. GAAP requires firms to expense immediately all internal expenditures for R&D costs. Alternatively, GAAP could require firms to capitalize and subsequently amortize all internal expenditures on R&D that have future potential. Why have standard setters chosen not to allow the capitalization alternative? How would analysts be better served if GAAP required capitalization of R&D costs?